(Q36987360)

17 August 2017

1 reference

title

Managing the neuropsychiatric complications of hepatitis C treatment (English)

1 reference

17 August 2017

3

Vicky Stergiopoulos

1 reference

17 August 2017

Sanjeev Sockalingam

1

1 reference

17 August 2017

Chekkera Shammi

series ordinal

2

1 reference

17 August 2017

publication date

1 October 2007

1 reference

British Journal of Hospital Medicine

17 August 2017

published in

1 reference

17 August 2017

volume

68

1 reference

17 August 2017

issue

10

1 reference

17 August 2017

page(s)

520-525

1 reference

Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Psychiatric disorders among veterans with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

A cognitive therapy conceptualization of panic disorder exacerbated by interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

The safety of valproic acid use for patients with hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Plasma levels of citalopram in depressed patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Major depressive disorder in hepatitis C: an open-label trial of escitalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Paroxetine for the prevention of depression induced by high-dose interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Psychiatric complications of long-term interferon alfa therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Interferon-induced depression: prevalence and management

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Interferon alpha (IFNalpha) and psychiatric syndromes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

Psychiatric comorbidity among hepatitis C-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.12968%2FHMED.2007.68.10.27321

10.12968/HMED.2007.68.10.27321

21 January 2018

Identifiers

DOI

0 references

1 reference